Alnylam Pharmaceuticals
Prezzo: 282.85Società e modello di business
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the development of therapies based on RNA interference (RNAi) technology. Its core products include treatments for genetic diseases and conditions related to liver and cardiovascular health. Major business segments encompass rare diseases and cardiovascular diseases, with primary revenue sources stemming from product sales and collaborations with other pharmaceutical companies.
Profilo di investimento
The investment profile of Alnylam Pharmaceuticals is more aligned with growth investors, given its focus on innovative therapies and potential market expansion. However, the high risk associated with its volatility and market performance may deter conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept higher risk for potential future gains.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 4.36 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- 6.4% ↑
- Sorpresa EPS
- 73.2% meglio del previsto
- Volatilità 20g
- 2.1% stabile
Traccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-03 02:58 | Mantieni | Vendi | Weak momentum and high risk overshadow potential growth. |
| 2026-05-24 02:31 | Vendi | Mantieni | Strong EPS surprise, but negative momentum raises concerns. |
| 2026-05-16 02:47 | Mantieni | Vendi | Weak momentum and high risk overshadow positive fundamentals. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-05-01 15:46 | Morgan Stanley | Target alzato | 360 → 370 | 301.4499 |
| 2026-05-01 13:04 | Bernstein | Target abbassato | 448 → 447 | 302.85001 |
| 2026-02-17 12:18 | Canaccord Genuity | Target alzato | 415 → 429 | 314.4 |
Ancora nulla